145 related articles for article (PubMed ID: 8129001)
1. Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2.
Thompson JT; Hiner CJ; Glaser BM; Gordon AJ; Murphy RP; Sjaarda RN
Am J Ophthalmol; 1994 Mar; 117(3):291-301. PubMed ID: 8129001
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade.
Rosa RH; Glaser BM; de la Cruz Z; Green WR
Am J Ophthalmol; 1996 Dec; 122(6):853-63. PubMed ID: 8956640
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study.
Glaser BM; Michels RG; Kuppermann BD; Sjaarda RN; Pena RA
Ophthalmology; 1992 Jul; 99(7):1162-72; discussion 1173. PubMed ID: 1495798
[TBL] [Abstract][Full Text] [Related]
4. The results of vitreous surgery for chronic macular holes.
Thompson JT; Sjaarda RN; Lansing MB
Retina; 1997; 17(6):493-501. PubMed ID: 9428011
[TBL] [Abstract][Full Text] [Related]
5. Vitrectomy, fluid-gas exchange and transforming growth factor--beta-2 for the treatment of traumatic macular holes.
Rubin JS; Glaser BM; Thompson JT; Sjaarda RN; Pappas SS; Murphy RP
Ophthalmology; 1995 Dec; 102(12):1840-5. PubMed ID: 9098285
[TBL] [Abstract][Full Text] [Related]
6. Full-thickness macular holes treated with vitrectomy and tissue glue.
Tilanus MA; Deutman AF
Int Ophthalmol; 1994-1995; 18(6):355-8. PubMed ID: 7642336
[TBL] [Abstract][Full Text] [Related]
7. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes.
Thompson JT; Glaser BM; Sjaarda RN; Murphy RP
Am J Ophthalmol; 1995 Jan; 119(1):48-54. PubMed ID: 7825689
[TBL] [Abstract][Full Text] [Related]
8. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes.
Lansing MB; Glaser BM; Liss H; Hanham A; Thompson JT; Sjaarda RN; Gordon AJ
Ophthalmology; 1993 Jun; 100(6):868-71; discussion 871-2. PubMed ID: 8510899
[TBL] [Abstract][Full Text] [Related]
9. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentered randomized clinical trial. The Vitrectomy for Treatment of Macular Hole Study Group.
Freeman WR; Azen SP; Kim JW; el-Haig W; Mishell DR; Bailey I
Arch Ophthalmol; 1997 Jan; 115(1):11-21. PubMed ID: 9006420
[TBL] [Abstract][Full Text] [Related]
10. Surgical treatment of full-thickness macular holes using autologous serum.
Wells JA; Gregor ZJ
Eye (Lond); 1996; 10 ( Pt 5)():593-9. PubMed ID: 8977788
[TBL] [Abstract][Full Text] [Related]
11. Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery.
Thompson JT; Smiddy WE; Williams GA; Sjaarda RN; Flynn HW; Margherio RR; Abrams GW
Ophthalmology; 1998 Apr; 105(4):700-6. PubMed ID: 9544645
[TBL] [Abstract][Full Text] [Related]
12. Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study.
Ie D; Glaser BM; Thompson JT; Sjaarda RN; Gordon LW
Ophthalmology; 1993 Dec; 100(12):1787-93. PubMed ID: 8259275
[TBL] [Abstract][Full Text] [Related]
13. Full-thickness macular hole formation in eyes with a pre-existing complete posterior vitreous detachment.
Gordon LW; Glaser BM; Ie D; Thompson JT; Sjaarda RN
Ophthalmology; 1995 Nov; 102(11):1702-5. PubMed ID: 9098265
[TBL] [Abstract][Full Text] [Related]
14. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.
Minihan M; Goggin M; Cleary PE
Br J Ophthalmol; 1997 Dec; 81(12):1073-9. PubMed ID: 9497468
[TBL] [Abstract][Full Text] [Related]
15. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2.
Thompson JT; Glaser BM; Sjaarda RN; Murphy RP; Hanham A
Ophthalmology; 1994 Jul; 101(7):1195-200. PubMed ID: 8035983
[TBL] [Abstract][Full Text] [Related]
16. Baseline characteristics, natural history, and risk factors to progression in eyes with stage 2 macular holes. Results from a prospective randomized clinical trial. Vitrectomy for Macular Hole Study Group.
Kim JW; Freeman WR; el-Haig W; Maguire AM; Arevalo JF; Azen SP
Ophthalmology; 1995 Dec; 102(12):1818-28; discussion 1828-9. PubMed ID: 9098283
[TBL] [Abstract][Full Text] [Related]
17. Fundus photographic and fluorescein angiographic characteristics of pseudoholes of the macula in eyes with epiretinal membranes.
Klein BR; Hiner CJ; Glaser BM; Murphy RP; Sjaarda RN; Thompson JT
Ophthalmology; 1995 May; 102(5):768-74. PubMed ID: 7777276
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange.
Blumenkranz MS; Ohana E; Shaikh S; Chang S; Coll G; Morse LS; De Bustros S
Ophthalmic Surg Lasers; 2001; 32(3):198-207. PubMed ID: 11371086
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic study of bilateral macular holes treated with pars plana vitrectomy and gas tamponade.
Funata M; Wendel RT; de la Cruz Z; Green WR
Retina; 1992; 12(4):289-98. PubMed ID: 1485013
[TBL] [Abstract][Full Text] [Related]
20. Treatment of idiopathic macular holes by induced posterior vitreous detachment.
Chan CK; Wessels IF; Friedrichsen EJ
Ophthalmology; 1995 May; 102(5):757-67. PubMed ID: 7777275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
